Check out all of the biosimilar information for rheumatologists and health care providers who work within Primary Care.

First Trastuzumab Biosimilar, Ogivri, Approved by FDA

(FDA News Release, December 1, 2017)

3 Facts About Biosimilars Pharmacists Should Know

Pharmacy Times (03/08/16) Ross, Meghan

Amgen's Humira Biosimilar Accepted for FDA Review

Bloomberg BNA (01/26/16) Aquino, John T.

Biosimilar Issues on the FDA Guidance Agenda for 2016

U.S. Food and Drug Administration (01/22/2016)

Biosimilar Therapies in Inflammatory Bowel Disease: Should We Care About Patient Profile?

Expert Review of Clinical Immunology (02/16) Fiorino, Gionata; Fazio, Maria; Danese, Silvio

Biosimilars in Development Near End of Phase 3 Trials

Managed Care (02/01/16) Adams, Katherine T.

Biosimilars in the Management of Neutropenia: Focus on Filgrastim

Biologics: Targets and Therapy (02/18/2016) Vol. 10, P. 17; Caselli, D.; Cesaro, S.; Aricò, M.

Biosimilars: Payer and Formulary Considerations

Ross M. Miller, MD, MPH, FACPERoss M. Miller, MD, MPH, FACPE
Medical Advisor
California Department of Health Care Services
Los Angeles, California

Clinical and Regulatory Perspectives on Biosimilar Therapies and Intended Copies of Biologics in Rheumatology

Rheumatology International (02/27/2016) Mysler, E.; Pineda, C.; Horiuchi, T.

Clinician and Payer Perspectives on the First Biosimilar Approved in the US


Gary H. Lyman, MD, MPHGary H. Lyman, MD, MPH
Hutchinson Institute for Cancer Outcomes Research
Professor of Medicine
University of Washington


Edmund J. Pezalla, MD, MPHEdmund J. Pezalla, MD, MPH
Vice President
Pharmaceutical Policy and Strategy
Hartford, Connecticut

CME/CE Multimedia Modules

Welcome to Biologics and Biosimilars: Preparing for the Future!

This is a series of 8 interactive modules. Each module focuses on a different topic and answers questions clinicians commonly ask about biosimilars. It is highly recommended that you complete the entire curriculum.

Module 7
Module 5
Module 6
Module 3
Module 4
Module 2
Module 1
Module 8

CMS Moves on Biosimilar Reimbursement

Pharmacy Practice News (01/29/16) Blum, Karen

Comprehensive Review of Biosimilars vs. Reference Biologics

jonathan kayJonathan Kay, MD
Director of Clinical Research
Rheumatology Division
UMASS Memorial Medical Center
Professor of Medicine
University of Massachusetts Medical School
Worcester, Massachusetts

Core Concepts: Biosimilars

Proceedings of the National Academy of Sciences (12/15/15) Vol. 112, No. 50, P. 15261; Ornes, Stephen

Development, Safety, and Efficacy of Biosimilar Adalimumab: The Data So Far

Biosimilars (01/29/2016) Vol. 06, P. 01; Gabbani, Tommaso; Deiana, Simona; Bagnoli, Siro

Evaluation of Immunogenicity of LY2963016 Insulin Glargine Compared With Lantus Insulin Glargine in Patients With Type 1 or Type 2 Diabetes Mellitus

Diabetes, Obesity, and Metabolism (02/01/2016) Vol. 18, No. 2, P. 159; Ilag, LL; Deeg, MA; Costigan, T

FDA Approval of a Biosimilar to Enbrel®

(FDA News Release, August 30, 2016)

Implementation of the Biosimilars Provisions of the ACA — Where Are We Now?

Health Affairs Blog (12/14/15) Wynne, Billy

Infliximab-qbtx Approved by FDA

(BUSINESS WIRE Release, December 13, 2017)

Nearly Half of U.S. Physicians Say They Will Prescribe More Biosimilars, According to New Data From InCrowd

Marketwired (03/03/16)

New & Noteworthy